28.09.2017 • Topics

M&A in Pharma and CRO/CMO Industry

(c) cacaroot/Fotolia
(c) cacaroot/Fotolia

Challenges caused by a merger or an acquisition can be manifold, no matter whether it is your own organization that is going through M&A and the integration phase or any of your outsourcing partners or customers. Distractions or disruptions are pre-programmed and sometimes inevitable, thus, it gets hard to maintain business as usual. In such a phase it is important not to lose focus on customer relationship and ongoing projects. CHEManager International asked executives and opinion leaders in the chemical and pharmaceutical market to share their experience and advice. For instance, we wanted to know:

  • Will the consolidation in the pharmaceutical industry level off or will it even intensify?
  • Does the consolidation in the pharma industry create a necessity for CROs/CMOs to consolidate?
  • How big of an issue is a merger or an acquisition for ongoing projects?
  • How can outsourcing partners maintain their focus and guarantee confidentiality in their projects?

Read the insightful answers of the experts here

Book

Innovation Management in Sustainable Chemistry

Innovation Management in Sustainable Chemistry

Comprehensive resource on sustainable chemistry, bridging the skill gap between academic science education and innovation and entrepreneurship

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read